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The economic impact of periprosthetic infection in 
total hip arthroplasty
Background: Periprosthetic joint infection (PJI) is the third leading cause of total 
hip arthroplasty (THA) failure. Although controversial, 2-stage revision remains the 
gold standard treatment for PJI in most situations. To date, there have been few 
studies describing the economic impact of PJI in today’s health care environment. 
The purpose of the current study was to obtain an accurate estimate of the institu-
tional cost associated with the management of PJI in THA and to assess the eco-
nomic burden of PJI compared with primary uncomplicated THA.
Methods: We conducted a review of primary THA cases and 2-stage revision THA 
for PJI at our institution. Patients were matched for age and body mass index. All 
costs associated with each procedure were recorded. Descriptive statistics were used to 
summarize the collected data. Mean costs, length of stay, clinic visits and readmission 
rates associated with the 2 cohorts were compared.
Results: Fifty consecutive cases of revision THA were matched with 50 cases of 
uncomplicated primary THA between 2006 and 2014. Compared with the primary 
THA cohort, PJI was associated with a significant increase in mean length of hos-
pital stay (26.5 v. 2.0 d, p < 0.001), mean number of clinic visits (9.2 v. 3.8, 
p < 0.001), number of readmissions (12 v. 1, p < 0.001) and average overall cost 
(Can$38 107 v. Can$6764, t = 8.3, p < 0.001).
Conclusion: Treatment of PJI is a tremendous economic burden. Our data suggest 
a 5-fold increase in hospital expenditure in the management of PJI compared with 
primary uncomplicated THA.
Contexte  : L’infection articulaire périprothétique (IAP) arrive au troisième rang 
des principales causes d’échec de l’arthroplastie (ou prothèse) totale de la hanche 
(PTH). Même si elle est controversée, la révision en 2 étapes demeure le traitement 
standard pour l’IAP dans la plupart des cas. À ce jour, peu d’études ont décrit 
l’impact économique de l’IAP dans l’environnement actuel des soins de santé. Le 
but de la présente étude était d’obtenir une estimation précise des coûts institution-
nels associés à la prise en charge de l’IAP dans la PTH et d’évaluer le fardeau 
économique de l’IAP comparativement à une PTH primaire non compliquée.
Méthodes : Nous avons passé en revue les cas de PTH primaire et de révision 
de PTH en 2 étapes pour cause d’IAP dans notre établissement. Les patients 
ont été assortis selon l’âge et l’indice de masse corporelle. Tous les coûts associés 
à chaque intervention ont été consignés. Des statistiques descriptives ont servi 
à résumer les données recueillies. Nous avons comparé les coûts moyens, la 
durée des séjours, les visites à la clinique et les taux de réadmission associés aux 
2 cohortes.
Résultats  : Cinquante cas consécutifs de révision de PTH ont été assortis à 
50 cas de PTH primaire non compliquée entre 2006 et 2014. Comparativement 
à la cohorte de PTH primaire, les cas d’IAP ont été associés à une augmentation 
significative de la durée moyenne du séjour hospitalier (26,5 j c. 2,0 j, p < 0,001), 
du nombre moyen de visites à la clinique (9,2 c. 3,8, p < 0,001), du nombre 
des réadmissions (12 c. 1, p < 0,001) et du coût global moyen (38 107 $ CA 
c. 6764 $ CA, t = 8,3, p < 0,001).
Conclusion  : Le traitement de l’IAP représente un énorme fardeau économique. 
Selon nos données, les dépenses hospitalières associées à sa prise en charge sont 5 fois 
plus grandes que pour la PTH primaire non compliquée. 
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D eep infection is a devastating complication in total hip arthroplasty (THA) resulting in significant patient and institutional burden. Current litera-
ture suggests that the incidence of periprosthetic joint 
infection (PJI) is 1%–2%, and it is projected to increase 
as the population ages and as indications for THA con-
tinue to expand.1–6 In North America, 2-stage revision 
surgery remains the gold standard in treatment, leading 
to successful eradication of infection in up 90% of 
patients with PJI.7,8 Most of these revisions are performed 
in tertiary care centres by surgeons with specialty training 
in adult reconstructive surgery.9 By its nature, treatment 
is a costly institutional endeavour, requiring multiple sur-
geries and hospital admissions. Previous studies suggest a 
2- to 4-fold increase in health care expenditure for PJI 
compared with primary uncomplicated THA.6,10,11,12 
These expenditures are largely driven by length of hospi-
tal stay, operating room expenses, implants and inpatient 
resource use. To date, much of our knowledge in this 
area has been obtained from large-volume databases, 
where costs have often been derived from hospital bill-
ings rather than from direct institutional case costing 
data.6,7,11 This makes it difficult to extrapolate findings to 
other facilities and health care models and, in turn, may 
limit our ability to identify potential for cost containment 
at the institutional level. Cost data have become particu-
larly important with the emergence of quality-based 
funding or bundled reimbursement models, which 
require surgeons to be cost conscious while providing 
high-quality, equitable care. With this in mind, the pur-
pose of our study was to obtain an accurate estimate of 
the institutional cost associated with the management of 
PJI in THA and to assess the economic burden of PJI 
compared with primary THA with respect to direct insti-
tutional cost and hospital resource utilization.
Methods
This was a single-centre, retrospective study that com-
pared patients who underwent 2-stage revision for infec-
tion with a cohort of patients matched on age and body 
mass index (BMI) who underwent uncomplicated primary 
THA between 2006 and 2014. The diagnosis of PJI was 
made using the Musculoskeletal Infection Society’s cri-
teria.13 Osteoarthritis was the indication for all primary 
THA. Patients with prior ipsilateral revision hip surgery 
and patients who died before second-stage revision were 
excluded. All patients had a minimum follow-up of 2 years. 
All cost- and procedure-related data were obtained from 
an institutional database at a single Canadian academic 
centre. Information in this database reflects the practices of 
6 fellowship-trained arthroplasty surgeons.
We identified 61 consecutive cases of infected THA 
between 2012 and 2014. Fifty patients met the inclusion 
criteria and were thus entered into our analysis. A compar-
ative cohort of 50 consecutive cases of primary THA was 
matched to the cohort of patients with infected THA on 
the basis of age and body mass index (BMI) and was used 
to establish a control group. Data pertaining to inpatient 
resource utilization were collected by a single independent 
reviewer, using an electronic medical record system. Unit 
costs pertaining to operating time, operative equipment, 
implants, antibiotics, anticoagulation, transfusions, postop-
erative recovery, length of hospital stay, readmission rates, 
inpatient consults, inpatient physical therapy and investiga-
tions (including imaging and blood work) were obtained 
using current administrative data from the case costing 
department at our institution.
Statistical analysis
Microsoft Excel for Mac (version 15.31) was used for all 
analy ses. Descriptive statistics including means and ranges 
were calculated to describe each cohort. Patients with PJI 
were compared with the matched cohort of patients who 
underwent primary THA using the χ2 test (for categorical 
variables) and the t test (for continuous variables). The 
Mann–Whitney test was applied where nonparametric data 
were identified. The study was powered at 0.90 with an α 
of 0.05 to detect a difference in overall cost between 
cohorts. Statistical significance was considered at a p value 
of less than 0.05.
Results
Sixty-one cases of infected THA were reviewed for entry 
into this study; 11 of them were eventually excluded. 
Seven patients were excluded because an initial irrigation 
and débridement was performed at an outside institution 
before the patient presented to our centre for staged 
revision. Three patients were excluded because they died 
before stage 2 revision could be completed, and 1 patient 
was excluded after opting not to move forward with 
stage 2. After exclusions, 50 cases of infected THA were 
entered into our analysis and were compared with 
50 cases of primary uncomplicated THA. The mean age 
and BMI of patients was 64 (range 50–83) years and 
32 (range 19–41) in the revision cohort and 67 (range 
52–82) years and 29 (range 19–39) in the primary THA 
cohort, respectively (Table 1).








Age, yr 67 (52–82) 64 (50–83) 0.13
BMI 29 (19–39) 32 (19–41) 0.12
BMI = body mass index; THA = total hip arthroplasty.
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The average cost of 2-stage revision for infected THA 
was Can$38 107 (range $17 789–$118 247). This pro ced-
ure was 5.6 times more costly than the average primary 
THA (Can$6764 [range $5823–$8523]) and the differ-
ence between groups was significant (p < 0.001) (Table 2). 
The Mann–Whitney test was applied to correct for non-
parametric data and also indicated statistical significance, 
with the median cost of 2-stage revision being greater 
than the median cost of primary THA (Can$29 711 v. 
Can$6634, z = 7.03, p < 0.001). Six patients (12%) in the 
cohort with infected THA required at least 1 repeat stage 
1 revision before receiving a definitive second-stage sur-
gery. Staphylococcus aureus was the most commonly iso-
lated organism (38%) with the methicillin-resistant form 
(MRSA) accounting for 22% of the infections in the 
entire cohort of patients with infected THA. The average 
cost associated with management of MRSA PJI was simi-
lar to the cost of managing other isolated pathogens 
(Can$39 558 v. Can$40 065). PJI was also associated with 
a significant increase in mean length of hospital stay (26.5 
v. 2.0 d, p < 0.001), mean number of clinic visits (9.2 v. 
3.8,  p  <  0.001) and number of  readmissions 
(12 v. 1, p < 0.001) when patients in the infected THA 
group were compared with those who underwent primary 
THA (Table 3). Inpatient resource use was also greater 
among the patients with infected THA. There was an 
8-fold increase in costs associated with laboratory testing 
and imaging (Can$898 v. Can$116) and a 20-fold 
increase in medications costs secondary to prolonged 
antibiotic and anticoagulant use while in hospital 
(Can$1167 v. Can$54) (Table 4).
discussion
As annual THA volumes continue to increase, so too will 
the number of revision procedures for management of 
PJI. For every 9 patients who undergo primary THA, it 
is estimated that 1 is admitted for revision.14 Peripros-
thetic joint infection is the third leading cause of failure 
following primary THA,14 and treatment in the United 
States alone was projected to impart a financial burden in 
excess of US$400 million by 2020.6
In our study, 2-stage revision for PJI was associated with 
a greater than 5-fold increase in hospital expenditure when 
compared with primary uncomplicated THA. The bulk of 
this expense (83%) was attributed to hospital bed charges, 
operating room services and implant use. Patients who 
underwent treatment for PJI were also more likely to be 
readmitted, had more outpatient clinic visits and consumed 
more resources than those who underwent primary THA. 
To our knowledge, this is one of few studies to evaluate the 
cost of PJI in THA using direct institutional case costing.10,11 
This differs from most prior studies, which derived esti-
mates from institutional billing data. This type of data may 
vary greatly across institutions and its interpretation requires 
knowledge of centre-specific cost-to-charge ratios.12 Direct 
case costing, on the other hand, better reflects consumed 
resources and services and thus more accurately reflects true 
institutional burden. In theory, these data should be similar 
among institutions that serve similar regions and operate 
with similar practice patterns. Although the cost of deliver-
ing orthopedic care is substantially lower in Canada than in 
other countries, the relative cost of primary and 2-stage revi-
sion is remarkably similar to that observed in the US. This 
suggests that our data are generalizable and thus may be 
used to guide future resource allocation and budget plan-
ning at tertiary centres that offer similar care. 
Our study corroborates the findings of previously pub-
lished work. Bozic and Ries10 conducted a retrospective cost 
Table 2. Average cost of total hip arthroplasty
Category
Cohort; cost, Can$, mean (range) 
p valuePrimary THA Infected THA















THA = total hip arthroplasty.
Table 3. Length of hospital stay, clinic visits and readmissions 




p valuePrimary THA Infected THA
Mean length of hospital 
stay, d
2.0 26.5 < 0.001
Mean no. of clinic visits 3.8 9.2 < 0.001
No. of patients 
readmitted
1 12 < 0.001
THA = total hip arthroplasty.
Table 4. Summary of expenses in total hip arthroplasty
Resource
Cohort; cost, Can$, mean (range)
Primary THA Infected THA












Hospital bed charges 1394  
(719–2624)
17 423  
(3135–65 221)












THA = total hip arthroplasty.
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analysis involving a cohort of 25 patients who underwent 
2-stage revision for periprosthetic hip infection. In this 
study the total hospital cost associated with treatment of 
PJI was 4.4 times greater than the cost of primary THA 
(US$96 166 v. US$21 654, p < 0.001). These authors also 
noted a significant increase in length of hospital stay 
(28.2 v. 6.2 d, p < 0.001) and outpatient visits among 
patients treated with 2-stage revision (54.6 v. 17.2, p < 0.001). 
Unlike us, these authors did not comment on other specific 
factors that contributed to the cost of care in PJI.
Most recently, Kapadia and colleagues11 published the 
results of a retrospective study examining the economic 
impact of periprosthetic hip infection. In this study, 
16 patients who underwent 2-stage revision were compared 
with a cohort of patients who underwent primary uncom-
plicated THA. They analyzed a combination of billing and 
direct cost data from their institution. Treatment of peri-
prosthetic infection was found to be 3.5 times more costly 
than primary THA (US$88 623 v. US$25 659, p < 0.001). 
Similar to our study, Kapadia and colleagues11 also 
reported longer hospital stays (7.6 v. 3.3 d, p = 0.02), more 
readmissions (2 v. 0, p < 0.0001) and a significant increase 
in resource utilization among patients with periprosthetic 
hip infection.11 Interestingly, average length of stay in the 
infected cohort was much shorter than we observed in our 
study (7.6 v. 26.5 d). This is an important finding given 
that both studies identified length of hospital stay as the 
greatest contributing factor to the total cost of care in 
periprosthetic hip infection. Although this may indicate 
a difference in practice pattern, it may also simply reflect a 
difference in the way length of hospital stay was defined in 
each study. In our study, length of hospital stay was calcu-
lated as the sum total of days spent in hospital across all 
stages of revision. It should be noted that all patients were 
discharged home between stages.
Collectively, this body of work suggests that the eco-
nomic impact of PJI can be reliably estimated to be 
4–5 times the cost of primary THA. In doing so, this study 
also illustrates the need to further explore measures that may 
contain or reduce the burden PJI. With length of hospital 
stay contributing most significantly to the burden of care, 
institutions may benefit from the creation of well-defined 
clinical pathways, which better coordinate interdisciplinary 
care. In our experience, similar pathways have shortened 
hospital stays in primary arthroplasty and also enabled the 
delivery of safe outpatient surgery in select patients.
Single-stage revision is a cost-effective approach that 
continues to show promise in well-defined populations 
with PJI of the hip, knee and shoulder.14,15,16 In 2012, 
 Beswick and colleagues14 performed a systematic review of 
62 studies involving more than 4000 patients who were 
treated with 1- or 2-stage revision for periprosthetic hip 
infection. The incidence of recurrent infection was similar 
between groups (10.2% [95% confidence interval (CI) 
7.7%–12.9%] v. 8.6% [95% CI 4.5%–13.9%]). Although 
weakened by heterogeneity, these findings suggests the 
need for a prospective, randomized controlled trial to fur-
ther evaluate the efficacy of single-stage revision for PJI.
Limitations
The limitations of this study are largely related to its retro-
spective design. Most notably, this study is susceptible to 
selection bias. We aimed to minimize bias by entering 
patients into the study in consecutive fashion and by limit-
ing exclusion criteria. Cohorts were also matched for age 
and BMI in an attempt to limit the influence of variables 
that are known to effect resource utilization.17 The overall 
accuracy of our estimate is closely tied to the quality of 
available institutional data pertaining to resource utiliza-
tion. Our system enabled us to identify most resources 
using electronic medical records and intraoperative 
reports; however, some expenses (for bowel regimens, anti-
emetics and analgesics, for example) are reliably captured 
only prospectively. Although this is a limitation, it is 
unlikely to have had a significant impact on the magnitude 
of the difference between groups, given that these expenses 
are quite small relative to more significant drivers of cost 
such as LOS and operating room services. It should be 
noted that this study does not capture out-of-pocket 
patient expenses such as those related to prescription 
medi cation, respite care and time away from employment 
for both patients and their caregivers. Additionally, costs 
pertaining to home-based physiotherapy, antibiotic admin-
istration, wound care and peripherally inserted central line 
care were purposely not captured. We do not consider this a 
limitation given that our aim was to strictly describe the 
institutional cost burden of PJI in THA so that data can be 
used as a resource for institutional budget planning. In 
Canada, these outpatient expenses are directly funded by 
the provincial and territorial governments.
conclusion
Periprosthetic joint infection has a profound economic 
impact on tertiary care centres. Our data suggest a 5-fold 
increase in hospital expenditure in the management of PJI 
when compared with primary uncomplicated THA. The 
major cost-contributing factors are hospital bed, operating 
room and implant expenses, which together accounted for 
83% of total hospital expenditures in our study. These data 
may be useful in guiding future resource allocation decisions 
and institutional budget planning for THA. This study also 
highlights the need for further investigation of potential cost-
containing measures in the management of PJI.
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